Literature DB >> 34097056

PD-L1 Expression Scoring: Non-Interchangeable, Non-Interpretable, Neither, or Both.

Niki Gavrielatou1, Saba Shafi1, Patricia Gaule1, David L Rimm1.   

Abstract

Entities:  

Year:  2021        PMID： 34097056      PMCID： PMC8634453          DOI： 10.1093/jnci/djab109

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   11.816


× No keyword cloud information.
  7 in total

1.  PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.

Authors:  Ming Sound Tsao; Keith M Kerr; Mark Kockx; Mary-Beth Beasley; Alain C Borczuk; Johan Botling; Lukas Bubendorf; Lucian Chirieac; Gang Chen; Teh-Ying Chou; Jin-Haeng Chung; Sanja Dacic; Sylvie Lantuejoul; Mari Mino-Kenudson; Andre L Moreira; Andrew G Nicholson; Masayuki Noguchi; Giuseppe Pelosi; Claudia Poleri; Prudence A Russell; Jennifer Sauter; Erik Thunnissen; Ignacio Wistuba; Hui Yu; Murry W Wynes; Melania Pintilie; Yasushi Yatabe; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2018-05-22       Impact factor: 15.609

2.  Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer.

Authors:  Karina Kulangara; Nancy Zhang; Ellie Corigliano; Lindsay Guerrero; Stephanie Waldroup; Dipeshkumar Jaiswal; Malinka Jansson Ms; Supriya Shah; Debra Hanks; Jiangdian Wang; Jared Lunceford; Mary J Savage; Jonathan Juco; Kenneth Emancipator
Journal:  Arch Pathol Lab Med       Date:  2018-07-20       Impact factor: 5.534

3.  Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer.

Authors:  Emily S Reisenbichler; Gang Han; Andrew Bellizzi; Veerle Bossuyt; Jane Brock; Kimberly Cole; Oluwole Fadare; Omar Hameed; Krisztina Hanley; Beth T Harrison; M Gabriela Kuba; Amy Ly; Dylan Miller; Mirna Podoll; Anja C Roden; Kamaljeet Singh; Mary Ann Sanders; Shi Wei; Hannah Wen; Vasiliki Pelekanou; Vesal Yaghoobi; Fahad Ahmed; Lajos Pusztai; David L Rimm
Journal:  Mod Pathol       Date:  2020-04-16       Impact factor: 7.842

4.  Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

Authors:  Javier Cortes; David W Cescon; Hope S Rugo; Zbigniew Nowecki; Seock-Ah Im; Mastura Md Yusof; Carlos Gallardo; Oleg Lipatov; Carlos H Barrios; Esther Holgado; Hiroji Iwata; Norikazu Masuda; Marco Torregroza Otero; Erhan Gokmen; Sherene Loi; Zifang Guo; Jing Zhao; Gursel Aktan; Vassiliki Karantza; Peter Schmid
Journal:  Lancet       Date:  2020-12-05       Impact factor: 79.321

5.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

6.  A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.

Authors:  David L Rimm; Gang Han; Janis M Taube; Eunhee S Yi; Julia A Bridge; Douglas B Flieder; Robert Homer; William W West; Hong Wu; Anja C Roden; Junya Fujimoto; Hui Yu; Robert Anders; Ashley Kowalewski; Christopher Rivard; Jamaal Rehman; Cory Batenchuk; Virginia Burns; Fred R Hirsch; Ignacio I Wistuba
Journal:  JAMA Oncol       Date:  2017-08-01       Impact factor: 31.777

7.  PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.

Authors:  Hope S Rugo; Sherene Loi; Sylvia Adams; Peter Schmid; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Eric P Winer; Mark M Kockx; Dieter Peeters; Stephen Y Chui; Jennifer C Lin; Anh Nguyen Duc; Giuseppe Viale; Luciana Molinero; Leisha A Emens
Journal:  J Natl Cancer Inst       Date:  2021-06-07       Impact factor: 13.506
  7 in total
  1 in total

Review 1.  Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.

Authors:  Ichidai Tanaka; Masahiro Morise
Journal:  Int J Mol Sci       Date:  2021-12-27       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.